A mutant hydroxylase with increased activity and greater substrate specificity towards phenylacetyl-7-ADCA derivatives for the production of phenylacetyl-7-HACA derivatives, which carries one or more amino acid modification at residue positions when compared with certain wild type hydroxylase from certain groups of residues. Also disclosed is a process for the preparation of deacetyl cephalosporanic acid from the corresponding deacetoxy cephalosporanic acid that includes an enzyme of the present invention. Also provided is a method for the production and processing of such enzymes.
The present invention relates to an improved process for the preparation of Tazobactam of formula (I) having reduced content of cresol. (Formula I) (I)
C07D 499/87 - Compounds being unsubstituted in position 3 or with substituents other than only two methyl radicals attached in position 3, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
3.
AN IMPROVED PROCESS FOR THE PREPARATION OF CARBAPENEM ANTIBIOTIC
The present invention provides an improved process for the preparation Ertapenem monosodium of formula (I) having purity greater than 98.5% and having pharmaceutically acceptable level of palladium and residual solvent. (I)
The present invention relates to an improved process for the preparation of Biapenem of Formula (I) having reconstitution time less than 25 seconds. (Formula (I))
C07D 519/06 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or containing at least one condensed beta-lactam ring system, provided for by groups , or , e.g. a penem or a cepham system
Polymorphs of Ceftiofur sodium as a crystalline product and a process for the preparation of polymorphs of crystalline Ceftiofur sodium of formula (I).
C07D 501/36 - Methylene radicals, substituted by sulfur atoms
A61K 31/546 - Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine containing further heterocyclic rings, e.g. cephalothin
6.
Crystalline sodium salt of cephalosporin antibiotic
The present invention relates to novel polymorph of Ceftiofur sodium as a crystalline product. The present invention also provides a process for the preparation of novel polymorphs of crystalline Ceftiofur sodium of formula (I).
A61K 31/546 - Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine containing further heterocyclic rings, e.g. cephalothin
7.
AN IMPROVED PROCESS FOR THE PREPARATION OF ESOMEPRAZOLE MAGNESIUM DIHYDRATE
The present invention provides an improved process for the preparation of Esomeprazole magnesium dihydrate of formula (I) and its intermediates particularly 5-methoxy-2-[[(4-methoxy-315-dimethyl-2-pyridinyl)-methyl]thio]-1H- benzimidazole (pro-chiral) compound of formula (II).
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
8.
AN IMPROVED PROCESS FOR THE PREPARATION OF CARBAPENEM ANTIBIOTIC
The present invention relates to an improved process for the preparation of the carbapenem antibiotic of formula (I) or its salts, hydrates and esters. The present invention further provides novel crystalline form of compound of general formula (III), wherein R3 is p-nitrobenzyloxy carbonyl.
C07D 477/06 - Preparation from compounds already containing the ring or condensed ring systems, e.g. by dehydrogenation of the ring, by introduction, elimination or modification of substituents
C07D 207/08 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
9.
PHARMACEUTICAL COMPOSITION COMPRISING CILASTATIN, A CHELATING AGENT AND OPT. A PENEM ANTIBIOTIC
The present invention refers to a stable pharmaceutical composition comprising cilastatin, a chelating agent and opt. a penem antibiotic (preferably imipenem). Additionally, the composition can also contain a buffer.
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
The present invention relates to novel polymorphs of Ceftiofur sodium as a crystalline product. The present invention also provides a process for the preparation of novel polymorphs of crystalline Ceftiofur sodium of formula (I).
The present invention relates to an improved process for the preparation of Duloxetine and its intermediates (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2- thienyl)propanamine by reacting (S)-(-)-N,N-dimethyl-3-(2-thienyl)-3-. hydroxypropanamine with 1-fluoronaphthalene in the presence of a base; wherein the improvement lies in conducting the reaction in the absence of solvent.
The present invention relates to a process for the preparation of a psychotropic agent Paliperidone. Preferably, this invention relates to a method for the purification of Paliperidone by making its acid addition salts.
The present invention relates to an improved process for the preparation of Tadalafil intermediate (1R,3R)Methyl-1,2,3,4-tetrahydro-1-(3,4-methylenedioxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate of formula III comprising a modified Pictet-Spengler reaction between the compound of formula II and piperonal in a mixture of aromatic hydrocarbon solvent and a glycol.
The present invention provides a process for the preparation of Naratriptan hydrochloride which comprises decarboxylation of 5-{2-[(methylamino) sulfonyl] ethyl}-1H-indole-2-carboxylic acid to get 2-(1H-indol-5-yl)-N-methylethanesulfonamide using sulfolane as a solvent, and further reacting 2-(1H-indol-5-yl)-N-methylethanesulfonamide to obtain Naratriptan hydrochloride.
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
The present invention relates to a modified esterase with enhanced deacetylation activity for 7-ACA or its acyl amino derivative and cephalosporin C for the production of HACA and 3-deacetyl cephalosporin C, respectively, which carries one or more amino acid modification at residue positions when compared with the wild type esterase (MTCC 121) from the following group of residues, Aspartic acid at position 43, Methionine at position 138, Tyrosine at position 222 and Arginine at position 231.
The present invention provides a process for the preparation of the compound of formula (I) wherein HX represents HI, HCl, H2SO4 and the like. The compound of formula (I) is an important intermediate in the preparation of Cefepime.
The present invention relates to quick dissolve pharmaceutical compositions. More particularly the invention relates to quick dissolve pharmaceutical compositions of memantine hydrochloride capable of dissolving in the oral cavity and process for preparing such compositions. The quick dissolve pharmaceutical compositions of memantine hydrochloride contain at least one water-soluble diluent in particular a mono- or disaccharide and at least one disintegrant and optionally other pharmaceutically acceptable excipients.
The present invention relates to an improved process for the preparation of Aprepitant of formula (I) and its intermediates. More particularly the present invention relates to the preparation of 3-(-S)-(4-fluorophenyl)-4-benzyl-2-morpholinone of Formula (III) or its salts thereof by reacting N-benzyl-(S)-(4-fluorophenyl) glycine of formula (II) with 1,2 dibromoethane in presence of an organic base.
C07D 265/32 - 1,4-OxazinesHydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07C 229/36 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
20.
AN IMPROVED PROCESS FOR THE PREPARATION OF CEPHALOSPORIN ANTIBIOTIC
The present invention provides a process for the preparation of the compound of formula (I) and its salt and esters. More particularly, this present invention relates to an improved process for the preparation Cefcapene of formula (I) and its salt and esters.
C07D 501/34 - Methylene radicals, substituted by oxygen atomsLactones thereof with the 2-carboxyl group with the 7-amino radical acylated by carboxylic acids containing hetero rings
C07D 501/24 - 7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
C07D 277/28 - Radicals substituted by nitrogen atoms
The present invention relates to a mutant hydroxylase with increased activity and greater substrate specificity for phenylacetyl-7-ADCA for the production of phenylacetyl deacetyl-7- ACA, which carries one or more amino acid modification at residue positions when compared with the wild type hydroxylase from the following group of residues, Glutamic acid at position 16, Tyrosine at position 38, Proline at position 72, Threonine at position 90, Valine at position 150, Proline at position 186, Valine at position 221.Methionine at position 229, Threonine at position 273, Threonine at position 304 and Alanine at position 311.
The present invention relates to novel polymorph of Ceftiofur sodium as a crystalline product. The present invention also provides a process for the preparation of crystalline Ceftiofur sodium of formula (I).
C07D 501/36 - Methylene radicals, substituted by sulfur atoms
A61K 31/546 - Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine containing further heterocyclic rings, e.g. cephalothin
23.
A METHOD FOR THE PURIFICATION OF ROSUVASTATIN INTERMEDIATE
The present invention relates to a method for the purification of an intermediate of formula (1), which is useful for the preparation of Rosuvastatin and its pharmaceutically acceptable salts thereof, more particularly purification method comprises the addition of aqueous organic acid such as acetic acid under stirring conditions in presence of an organic solvent such as isopropyl ether or alternatively the purification method comprises the addition of aqueous alcohol such as methanol under stirring conditions in presence of an organic solvent such as isopropyl ether (Formula I)
The present invention relates to an improved process for the purification of Ropinirole hydrochloride of formula (I) using phosphorous containing reagent.
The present invention relates to an improved process for the preparation of N-[3-(3-cyanopyrazolo[ 1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide (Zaleplon) of formula (I), more particularly the present invention relates to a method for the purification of Zaleplon of formula (I), which is useful in medicine as an anxiolytic, sedative and skeletal muscle relaxing agent. Formula (I)
C07C 233/05 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
C07C 231/12 - Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
26.
AN IMPROVED PROCESS FOR THE PREPARATION OF CARBAPENEM ANTIBIOTIC
The present invention provides a process for the preparation of the carbapenem antibiotic of formula (I) or its salt in amorphous form. Formule(I) wherein R represents hydrogen or COOM and M represents hydrogen or sodium
C07D 207/08 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
C07D 207/09 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
The present invention relates to novel crystalline form of cephalosporin sulfate of the following formula and provides a process for preparing the same.
C07D 501/46 - Methylene radicals, substituted by nitrogen atomsLactams thereof with the 2-carboxyl groupMethylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atomQuaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
28.
AN IMPROVED PROCESS FOR THE PREPARATION OF GEMIFLOXACIN MESYLATE
The present invention relates to an improved process for the preparation of Gemifloxacin mesylate of formula (V). The present invention further provides novel intermediates of formula (II) and (IV), which are useful intermediates for the preparation of Gemifloxacin mesylate of formula (V) wherein R1 is linear or branched chain alkyl group having 1-3 carbon atoms.
C07D 501/24 - 7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
C07D 501/14 - Compounds having a nitrogen atom directly attached in position 7
C07C 229/20 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
C07C 229/22 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
30.
IMPROVED PROCESS FOR THE PREPARATION OF CEPHALOSPORIN ANTIBIOTICS
Abstract The present invention more particularly relates to a process for the preparation of cephalosporin antibiotics of the Formula (I) wherein R1 represents hydrogen, trityl, alkyl like CH3, CRaRbCOORc where Ra and Rb independently represent hydrogen or methyl and Rc represents hydrogen or (C1-C6) alkyl; R2 is carboxylate ion or COORd, where Rd represents hydrogen, ester or a counter ion which forms a salt; R3 represents hydrogen, CH3, CH2OCH3, CH2OCOCH3, CH=CH2, Formula (II).
The present invention relates to extended release formulations of venlafaxine hydrochloride, process for its preparation and to the use of the extended release formulations in treating various diseases or conditions.
Novel process for the preparation of the Faropenem of formula (I) where, R is hydrogen, alkali metal salts such as sodium or potassium, or prodrug residue.
C07D 499/893 - Compounds with a double bond between positions 2 and 3 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with a hetero ring or a condensed hetero ring system, directly attached in position 3
C07D 205/08 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
C07D 205/12 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
C07D 205/09 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
C07D 307/10 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
C07D 307/12 - Radicals substituted by oxygen atoms
The present invention relates to an improved process for the preparation of Lansoprazole of formula (I). More particularly, the present invention relates to a method for the purification of crude Lansoprazole in a solvent in presence of an alkali salt of an organic acid or in presence of an organic base such as piperidine or imidazole.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
34.
AN IMPROVED PROCESS FOR THE PREPARATION OF ALFUZOSIN HYDROCHLORIDE
The present invention relates to an improved process for the preparation of Alfuzosin hydrochloride of formula (I) by reacting N-(3-aminopropyl)-6,7-dimethoxy-N- methylquinazoline-2,4-diamine of formula (II) with 1-(tetrahydrofuran-2-ylcarbonyl)-1 H- imidazole of formula (IV) using acetonitrile as an organic solvent. This invention also relates to a method for the purification of N-(3-aminopropyl)-6,7-dimethoxy-N-methylquinazoline-2,4- diamine of formula (II), which is a key starting material of Alfuzosin hydrochloride by making its corresponding salt of formula (III) using an organic dicarboxylic acid in an alcoholic solvent wherein, A is denoted as a corresponding moiety of organic dicarboxylic acid.
C07D 405/00 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
35.
IMPROVED PROCESS FOR THE PREPARATION OF CEFEPIME INTERMEDIATE
The present invention provides a process for the preparation of the compound of formula (I) wherein X represents iodo or chloro. The compound of formula (I) is an important intermediate in the preparation of Cefepime or its pharmaceutically acceptable salts.
Novel 2-substituted methyl penam derivatives include the formula (I), their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their solvates, their pharmaceutically acceptable salts, and pharmaceutical compositions containing them; wherein A = C or N; Het is a three- to seven-membered heterocyclic ring; R1 represents carboxylate anion, or -COOR4 where R4 represents hydrogen, carboxylic acid protecting group or a pharmaceutically acceptable salt; R2 and R3 may be same or different and independently represent hydrogen, halogen, amino, alkyl, protected amino, optionally substituted alkyl, alkenyl, alkynyl and the like; R represents substituted or unsubstituted alkyl, alkenyl, aryl, aralkyl, cycloalkyl, heterocyclyl or heterocyclylalkyl.
C07D 499/87 - Compounds being unsubstituted in position 3 or with substituents other than only two methyl radicals attached in position 3, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
C07D 499/21 - Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. penicillins, penemsSuch ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a nitrogen atom directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
C07D 499/28 - Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. penicillins, penemsSuch ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a nitrogen atom directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with modified 2-carboxyl group
C07C 57/34 - Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings containing more than one carboxyl group
C07C 211/27 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
38.
AN IMPROVED PROCESS FOR THE PREPARATION OF ARIPIPRAZOLE
The present invention relates to an improved process for the preparation of Aripiprazole of formula (I), which is useful in the treatment of Schizophrenia. More particularly, the present invention relates to an improved process for the preparation of 7-(4-chlorobutoxy)-3,4-dihydrocarbostyril of formula (III) by reacting 7-hydroxy-3,4- dihydrocarbostyril of formula (II) with 1,4-dichlorobutane, in presence of inorganic base and solvent dimethylacetamide.
The present invention relates to an improved process for the preparation of Clopidogrel of Formula (I). More particularly, the present invention relates to an improved process for the preparation of Clopidogrel intermediate of formula (III) using triethylamine as an organic base in the absence of an organic solvent. Formula (I), Formula (III).
The present invention relates to an improved process for the preparation of Phenytoin Sodium of formula (I) by reacting Phenytoin with aqueous solution of Sodium hydroxide in presence of aqueous Sodium chloride.
C07D 233/74 - Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
41.
AN IMPROVED PROCESS FOR THE PREPARATION OF AMLODIPINE BESYLATE
The present invention provides a process for the preparation of amlodipine, which comprises purging of methylamine gas under stirring in phthaloyl amlodipine in presence of an organic solvent selected from the group consisting of toluene and isopropyl alcohol.
The present invention relates to a stable oral pharmaceutical composition. More particularly the invention relates to a stable oral pharmaceutical composition containing desloratadine and a process for preparing the stable oral pharmaceutical composition.
The present invention relates to an improved process for the preparation of Risperidone of formula (I) by condensing 6-fluoro-3- (4-piperidinyl)-l, 2- benzisoxazole with 3-(2-chloroethyl)-6, 7, 8, 9-tetrahydro-2-methyl-4H-pyrido ⏧1,2-a] pyrimidin-4-one in water and water immiscible solvents under basic conditions in the presence of a catalyst. This invention also relates to a method for purification of crude Risperidone by removing an impurity specifically named as 9-hydroxy Risperidone to undetectable level using acid chlorides and an organic base in a suitable solvent.
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
The present invention relates to the process for the preparation of monobactam antibiotic of formula (I). More particularly, the present invention relates to the preparation of Aztreonam of formula (I) from its precursor, tertiary butyl ester of Aztreonam of formula (II).
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
45.
AN IMPROVED PROCESS FOR THE PREPARATION OF DIPYRIDAMOLE
The present invention relates to an improved process for the preparation of Dipyridamole of formula (I) by reacting 2,6-Dichloro-4, 8-dipiperidinopyrimido (5,4- d) pyrimidine (DDH) with Diethanolamine (DEA) using l-Methyl-2-pyrrolidinone (NMP) as a solvent.
C07C 215/12 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic the nitrogen atom of the amino group being further bound to hydrocarbon groups substituted by hydroxy groups
The present invention relates to an improved process for the preparation of Levetiracetam of formula (I). More particularly, the present invention relates to a method for the purification of crude Levetiracetam using a solvent mixture of ethyl acetate and water.(I).
The present invention relates to an improved process for the preparation of Cilastatin Sodium of formula (I). The present invention also provides an isolation technique for Cilastatin acid from the reaction mixture.
C07C 319/14 - Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
C07C 233/46 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
C07D 501/24 - 7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
A61K 31/546 - Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine containing further heterocyclic rings, e.g. cephalothin
49.
AN IMPROVED PROCESS FOR THE PREPARATION OF GRANISETRON HYDROCHLORIDE
The present invention relates to an improved process for the preparation of Granisetron hydrochloride of formula (I). More particularly this invention relates to the preparation of Granisetron hydrochloride using methyl isobutyl ketone (MIBK) as a single solvent in presence of an organic base such as triethylamine.
The present invention relates to an improved process for the preparation of (-) Trans-N-methyl paroxetine of formula (I), which is an intermediate in the synthesis of Paroxetine of formula (II). (-) Trans-N-methyl paroxetine is prepared by reacting (-) trans sulphonate compound of formula (III) with 3,4-methylenedioxyphenol ('sesamol') of formula (IV) in the presence of base potassium carbonate using Methyl isobutyl ketone (MIBK) as solvent.
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
51.
MODIFIED EXPANDASE-HYDROXYLASE AND ITS APPLICATIONS
ABSTRACT The present invention relates to a mutant expandase-hydroxylase with increased activity and greater substrate specificity for Penicillin G and Phenyl acetyl 7-ADCA for the production of Phenyl acetyl - 7-ADCA and Deacetyl phenyl acetyl 7-ACA respectively; which carries one or more amino acid modification at residue positions when compared with the wild type expandase-hydroxylase from the following group of residues, Lysine at position 14, Serine at position 15, Threonine at position 20, Threonine at position 45, Glutamic acid at position 49, Lysine at position 56, Aspartic acid at position 70, Asparagine at position 72, Alanine at position 73, Valine at position 87, Lysine at position 93, Lysine at position 131, Tyrosine at position 185, Isoleucine at position 190, Tyrosine at position 203, Glutamic acid at position 212, Phenylalanine at position 226, Threonine at position 232, Lysine at position 247, Threonine at positon 260, Lysine at position 269, Asparagine at position 275, Asparagine at position 285, Tryptophan at position 282, Isoleucine at position 288, Threonine at position 293, Arginine at position 296, Lysine at position 310 and Threonine at position 332.
patents
